Intensity Therapeutics, Inc. Common stock Asset Resilience Ratio
Intensity Therapeutics, Inc. Common stock asset resilience ratio. Intensity Therapeutics, Inc. Common stock (INTS) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See INTS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Intensity Therapeutics, Inc. Common stock (2019–2024)
Asset resilience ratio of Intensity Therapeutics, Inc. Common stock from 2019 to 2024. This chart shows how Intensity Therapeutics, Inc. Common stock's Asset Resilience Ratio has changed over time. Read INTS total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Intensity Therapeutics, Inc. Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see INTS total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Intensity Therapeutics, Inc. Common stock maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Intensity Therapeutics, Inc. Common stock Industry Peers by Asset Resilience Ratio
Compare Intensity Therapeutics, Inc. Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Intensity Therapeutics, Inc. Common stock Asset Resilience Ratio by Year (2019–2024)
Intensity Therapeutics, Inc. Common stock asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Intensity Therapeutics, Inc. Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $4.78 Million | -- |
| 2023-12-31 | 35.96% | $6.22 Million | $17.30 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $1.76 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $10.15 Million | -- |
| 2019-12-31 | 50.68% | $4.56 Million | $9.01 Million | -- |
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is… Read more